文献速递乳腺外科

乳腺导管原位癌患者术前口服他莫昔芬与经皮4-羟基他莫昔芬的随机临床试验

Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2023-01-01

这项随机双盲2期术前窗口试验在多中心乳腺外科转诊机构进行,纳入100例雌激素受体阳性导管原位癌女性,随机接受口服他莫昔芬20 mg/d加凝胶安慰剂或经皮4-羟基他莫昔芬凝胶2 mg/d每侧乳房加口服安慰剂4至10周。主要终点为导管原位癌Ki-67标记指数绝对变化,经皮组治疗后Ki-67标记指数较口服组高3.3%(80%CI 2.1%-4.6%),超过非劣效界值2.6%,非劣效性未获确认,可能与他莫昔芬活性代谢物endoxifen暴露差异有关。

要点

  • 经皮4-羟基他莫昔芬凝胶在降低导管原位癌Ki-67标记指数方面未证实非劣效于口服他莫昔芬。
  • 经皮组治疗后Ki-67标记指数较口服组高3.3%(80%CI 2.1%-4.6%),超过预设非劣效界值2.6%。
  • 口服他莫昔芬组endoxifen中位数13.0 ng/g,经皮组0.3 ng/g(P<.001),可能解释疗效差异。

核心结论

  • 在这项随机临床试验中,4-羟基他莫昔芬凝胶相对于口服他莫昔芬的抗增殖非劣效性未获确认,可能由于endoxifen暴露差异所致。
  • 新的经皮给药方法必须递送更高药物量并/或包含最强效的代谢物。

研究设计与样本

  • 随机双盲2期术前窗口试验,于2017年5月31日至2021年1月27日在多中心乳腺外科转诊机构进行。
  • 408例雌激素受体阳性导管原位癌女性被接触,120例同意,100例开始研究治疗;90例完成治疗,75例可评估主要终点(口服他莫昔芬组40例,4-羟基他莫昔芬凝胶组35例)。
  • 随机分配至口服枸橼酸他莫昔芬20 mg/d加凝胶安慰剂,或4-羟基他莫昔芬凝胶2 mg/d每侧乳房加口服安慰剂,治疗4至10周后行导管原位癌切除。
  • 主要终点为导管原位癌Ki-67标记指数绝对变化;非劣效性采用协方差分析检验。

主要发现

  • 治疗后Ki-67标记指数在4-羟基他莫昔芬凝胶组较口服他莫昔芬组高3.3%(80%CI 2.1%-4.6%),超过非劣效界值2.6%。
  • 导管原位癌评分在口服他莫昔芬组降低16(95%CI -22至-9.4),在4-羟基他莫昔芬凝胶组降低1.8(95%CI -5.8至2.3)。
  • 乳腺深部4-羟基他莫昔芬中位数浓度在口服他莫昔芬组为5.7(IQR 4.0-7.9)ng/g,在4-羟基他莫昔芬凝胶组为3.8(IQR 1.3-7.9)ng/g,差异无统计学意义。
  • endoxifen在口服他莫昔芬组丰富,中位数13.0(IQR 8.9-20.6)ng/g,在4-羟基他莫昔芬凝胶组极少,中位数0.3(IQR 0-0.3)ng/g(P<.001)。
  • 口服他莫昔芬引起预期的血浆蛋白水平不良变化和血管舒缩症状,经皮组变化极小。

关键数值与推荐

  • 非劣效界值为2.6%。
  • 口服他莫昔芬剂量为20 mg/d,4-羟基他莫昔芬凝胶剂量为2 mg/d每侧乳房。
  • 治疗持续4至10周。
  • 主要终点为导管原位癌Ki-67标记指数绝对变化。

临床怎么用

  • 作者认为,新的经皮给药方法必须递送更高药物量并/或包含最强效的代谢物。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Oral tamoxifen citrate benefits women with ductal carcinoma in situ (DCIS), but concern about toxic effects has limited acceptance. Previous pilot studies have suggested transdermal 4-hydroxytamoxifen gel has equivalent antiproliferative efficacy to oral tamoxifen, with low systemic exposure. OBJECTIVE: To demonstrate that 4-hydroxytamoxifen gel applied to the breast skin is noninferior to oral tamoxifen in its antiproliferative effect in DCIS lesions. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, phase 2 preoperative window trial was performed at multicenter breast surgery referral practices from May 31, 2017, to January 27, 2021. Among 408 women with estrogen receptor-positive DCIS who were approached, 120 consented and 100 initiated study treatment. The most common reasons for nonparticipation were surgical delay, disinterest in research, and concerns about toxic effects. Data were analyzed from January 26, 2021, to October 5, 2022. INTERVENTION: Random assignment to oral tamoxifen citrate, 20 mg/d, and gel placebo or 4-hydroxytamoxifen gel, 2 mg/d per breast, and oral placebo, for 4 to 10 weeks, followed by DCIS resection. MAIN OUTCOMES AND MEASURES: The primary end point was absolute change in DCIS Ki-67 labeling index (Ki67-LI). Secondary end points included 12-gene DCIS Score, breast tissue tamoxifen metabolite concentrations, tamoxifen-responsive plasma protein levels, and patient-reported symptoms. Noninferiority of Ki67-LI reduction by 4-hydroxytamoxifen gel was tested using analysis of covariance; within- and between-arm comparisons were performed with paired t tests for mean values or the Wilcoxon rank sum test for medians. RESULTS: Of 90 participants completing treatment (mean [SD] age, 55 [11] years; 8 [8.9%] Asian, 16 [17.8%] Black, 8 [8.9%] Latina, and 53 [58.9%] White), 15 lacked residual DCIS in the surgical sample, leaving 75 evaluable for the primary end point analysis (40 in the oral tamoxifen group and 35 in the 4-hydroxytamoxifen gel group). Posttreatment Ki67-LI was 3.3% higher (80% CI, 2.1%-4.6%) in the 4-hydroxytamoxifen gel group compared with the oral tamoxifen group, exceeding the noninferiority margin (2.6%). The DCIS Score decreased more with oral tamoxifen treatment (-16 [95% CI, -22 to -9.4]) than with 4-hydroxytamoxifen gel (-1.8 [95% CI, -5.8 to 2.3]). The median 4-hydroxytamoxifen concentrations deep in the breast were nonsignificantly higher in the oral tamoxifen group (5.7 [IQR, 4.0-7.9] vs 3.8 [IQR, 1.3-7.9] ng/g), whereas endoxifen was abundant in the oral tamoxifen group and minimal in the 4-hydroxytamoxifen gel group (median, 13.0 [IQR, 8.9-20.6] vs 0.3 [IQR, 0-0.3] ng/g; P < .001). Oral tamoxifen caused expected adverse changes in plasma protein levels and vasomotor symptoms, with minimal changes in the transdermal group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, antiproliferative noninferiority of 4-hydroxytamoxifen gel to oral tamoxifen was not confirmed, potentially owing to endoxifen exposure differences. New transdermal approaches must deliver higher drug quantities and/or include the most potent metabolites. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02993159.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Khan SA, Mi X, Xu Y, et al. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial. JAMA Surg. 2023. PMID: 37870954. doi:10.1001/jamasurg.2023.5113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。